There is currently no evidence to support any specific therapeutic regimens for the recurrence of IgAN following KT although the Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group has suggested that treatment with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) may reduce the rate of decline in renal allograft function [6]. This evidence concerns the gene ACE and kidney disorder.